- Home
- PROV vs COEP Comparison
PROV vs COEP Comparison
Compare PROV & COEP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PROV | COEP |
|---|---|---|
| Founded | 1956 | 2017 |
| Country | United States | United States |
| Employees | N/A | 7 |
| Industry | Savings Institutions | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 103.6M | 72.7M |
| IPO Year | 2009 | N/A |
Fundamental Metrics
Financial Performance| Metric | PROV | COEP |
|---|---|---|
| Price | $15.92 | $12.48 |
| Analyst Decision | Hold | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $16.25 | N/A |
| AVG Volume (30 Days) | 5.4K | ★ 30.4K |
| Earning Date | 04-28-2026 | 01-01-0001 |
| Dividend Yield | ★ 3.52% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.47 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $4.14 | N/A |
| Revenue Next Year | $3.70 | N/A |
| P/E Ratio | $34.15 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.50 | $6.32 |
| 52 Week High | $16.64 | $21.41 |
Technical Indicators
Market Signals| Indicator | PROV | COEP |
|---|---|---|
| Relative Strength Index (RSI) | 45.05 | 48.81 |
| Support Level | $15.95 | $10.83 |
| Resistance Level | $16.30 | $13.12 |
| Average True Range (ATR) | 0.25 | 0.83 |
| MACD | -0.02 | 0.16 |
| Stochastic Oscillator | 41.04 | 52.61 |
Price Performance
Historical ComparisonAbout PROV Provident Financial Holdings Inc.
Provident Financial Holdings Inc is a holding company of Provident Savings Bank, F.S.B. It is a financial services company committed to serving consumers and small to mid-sized businesses in the Inland Empire region of Southern California. Its business activities consist of community banking, investment services and trustee services for real estate transactions. The group operates in Bank segment that include attracting deposits, offering banking services and originating and purchasing single-family, multi-family, commercial real estate, construction and, to a lesser extent, other mortgage, commercial business and consumer loans. Its evenues are derived from interest earned on its loan and investment portfolios, and fees generated through its community banking activities.
About COEP Coeptis Therapeutics Holdings Inc.
Coeptis Therapeutics Holdings Inc is a biopharmaceutical company developing cell therapy platforms for patients with cancer. The company's product portfolio consists of multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), a cell therapy technology (CD38-GEAR-NK), and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the company is developing with VyGen-Bio and medical researchers at the Karolinska Institutet.